Navigation Links
Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA
Date:1/16/2008

e information on PharmAthene, please visit http://www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "could"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include the possibility that PharmAthene may not eventually prevail in any legal proceedings; that PharmAthene may incur substantial costs involved in connection therewith; that SIGA-246 may not be licensed by PharmAthene; that it may not eventually prove to be effective or be capable of being marketed as a product, as well as risks detailed from time to time in PharmAthene's public disclosure filings with the U.S. Securities and Exchange Commission (the "SEC"). There can be no assurance that PharmAthene development efforts will succeed or that SIGA-246 or any other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of PharmAthene's public disclosure filings are available from its investor relations department.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
4. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
5. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
6. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
7. Burrill & Company Announces Promotions
8. Exelixis Announces Senior Management Promotions
9. Nastech Announces Promotion of Gordon Brandt, M.D. to President
10. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
11. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... lots and voluntary market withdrawal of one lot of ... is taking this action because some Daytrana patches do ... their release liner removal specification, and as a result, ...
(Date:12/3/2009)... -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer ... ), spoke at a conference on High-Risk Diabetic,Foot ... Beike is China,s leading,stem cell research and regenerative ... conference, organized by the Indian Podiatry Association (IPA), ...
(Date:12/2/2009)... YORK, Dec. 2 Reportlinker.com announces that ... in its catalogue: ,, Carbondioxide Incubators ... http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators are ... genetics, cancer, research, and other applications for ...
(Date:12/2/2009)... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion ... trial of Cotara® in patients with relapsed glioblastoma multiforme ... is a targeted monoclonal antibody linked to a radioisotope ... Cotara specifically targets cells at the center of ...
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
... Oct. 11 AMDL, Inc. (Amex:,ADL), headquartered ... and Jilin, China, through its wholly owned ... biopharma company that,engages in the development, manufacture ... AMDL announced today that JPI has,signed an ...
... Combined cardiac and vascular tissue processing revenues in the third, quarter ... 2006 ... FDA completes re-inspection, ATLANTA, Oct. 11 CryoLife, Inc. (NYSE: ... that product and preservation services revenues for the third quarter,of 2007 ...
... Nodal T-Cell Lymphoma Summary: Genmab Announced Today it has ... Refractory CTCL and has Received an Orphan Drug ... of Nodal T-Cell Lymphoma, COPENHAGEN, Denmark, October 11 ... of the ongoing pivotal,study of HuMax-CD4(R) (zanolimumab) to treat refractory ...
Other Biology Technology:AMDL Expands Drug Distribution in China With Additional Agreement, Valued at $2.3 Million Annually 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5Genmab Amends HuMax-CD4 Pivotal Study in CTCL 2Genmab Amends HuMax-CD4 Pivotal Study in CTCL 3
(Date:12/3/2009)... a social snubbing? Your genetics, not your friends, may be ... called opioids, relieve not only physical pain, but also some ... Faculty of 1000 Biology member Markus Heilig shows that small ... determine the intensity of people,s responses to social rejection. ...
(Date:12/3/2009)... NY A team of scientists from the U.S. ... and the Indian Institute of Science has made a ... information in DNA that is necessary to carry out ... 1, 2009 edition of Nature Structural & Molecular ...
(Date:12/2/2009)... evidence that people who smoke cigarettes over a long ... colorectal cancer, even after adjusting for other risk factors. ... smoke, or to quit as soon as possible," said ... emeritus, epidemiology and surveillance research at the American Cancer ...
Breaking Biology News(10 mins):Grooving down the helix 2Grooving down the helix 3Cigarette smoking increases colorectal cancer risk 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4
... India accelerates, tobacco advertising and marketing have been linked to ... 11, according to a study by researchers at The University ... Associations Between Tobacco Marketing and Use Among Urban Youth In ... Journal of Health Behavior. , Findings from an ...
... Inc. (OTC,Bulletin Board: STIY), a leader in electro-stun ... agreement with the Securities and Exchange,Commission., Stinger ... admitting or,denying wrongdoing and has agreed to an ... that no fines or monetary,sanctions were levied against ...
... and more of them are dying in West Greenland as ... a Penn State associate professor of biology. Post, who ... climate changes including global warming, based his conclusions on data ... corresponds to the timing of caribou births. The study, ...
Other Biology News:UT researchers find link between advertising and increased tobacco use among India's youth 2UT researchers find link between advertising and increased tobacco use among India's youth 3Global warming linked to caribou-calf mortality 2
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Biotin anti-human CD164...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: